Incannex Healthcare Inc. (NasdaqGM:IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NasdaqGM:IXHL). During the third quarter of fiscal year 2025, IXHL reported R&D expenses of $2.74M, down from $3.28M in the same quarter of the previous year, reflecting cost containment measures. SG&A expenses were $2.27M, compared to $4.14M in the prior year, driven by strategic cost-saving initiatives. The net loss for the quarter was reduced to $3.97M from $6.03M year-over-year, partly supported by improved operational efficiencies. Cash and cash equivalents totaled $6.7M, an increase from $2.1M as of 2Q24 end, due to recent financing activities and received R&D tax incentive payments.